AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28031192 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Mediterranean Diet Score (aMED)
Number of subjects: 1336
Study 28031192 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Healthy Diet Indicator (HDI)
Number of subjects: 1336
Study 28031192 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltic Sea Diet (BSD)
Number of subjects: 1336
Study 28031267 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Preerythrocytic Antigen UIS3
Number of subjects: 0
Study 28031267 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 28031277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac implantable electronic device (CIED)
Number of subjects: 489
Study 28031277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) burden ≥5 min
Number of subjects: 489
Study 28031277 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 489
Study 28031277 — intervention group
Group type: EXPERIMENTAL
Intervention: History of CABG
Number of subjects: 489
Study 28031392 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI assessment of blood-brain barrier (BBB) permeability changes
Number of subjects: 54
Study 28031392 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examination on day 5-7
Number of subjects: 54
Study 28031423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional Glenn (BDG)
Number of subjects: 168
Study 28031423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan
Number of subjects: 168
Study 28031423 — intervention group
Group type: COMPARATOR
Intervention: Pre-BDG
Number of subjects: 168
Study 28031441 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular neutrophil signature (upregulation of module M5.15) in SLE patients
Number of subjects: 0
Study 28031441 — intervention group
Group type: EXPERIMENTAL
Intervention: M5.15 activity in patients responding to treatment
Number of subjects: 0
Study 28031441 — intervention group
Group type: EXPERIMENTAL
Intervention: M5.15 activity in quiescent patients with a past history of LN
Number of subjects: 0
Study 28031441 — intervention group
Group type: EXPERIMENTAL
Intervention: M5.15 activation in patients with bacterial sepsis or ANCA-associated vasculitis
Number of subjects: 0
Study 28031441 — intervention group
Group type: EXPERIMENTAL
Intervention: M5.15 activation overall
Number of subjects: 0
Study 28031749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) treatment for 6 months
Number of subjects: 50
Study 28031816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg with peginterferon alfa-2b at 2 μg/kg/week
Number of subjects: 31
Study 28031860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention group (IG) - structured, individualized endurance training of ≥18 MET*h/week and personal nutritional counseling based on the Mediterranean diet.
Number of subjects: 60
Study 28031860 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - usual care, which includes one general counseling on healthy nutrition and benefits of regular physical activity.
Number of subjects: 60
Study 28031860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention group (IG)
Number of subjects: 60
Study 28031860 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 28032129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral crizotinib at dose levels of 100, 130, 165, 215, 280 and 365 mg/m
Number of subjects: 64
Study 28032216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedule and oral ondansetron 8 mg po q12 h
Number of subjects: 55
Study 28032216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant and ondansetron
Number of subjects: 55
Study 28032323 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine presence with Major Depressive Disorder (MDD)
Number of subjects: 227
Study 28032323 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine presence with Generalized Anxiety Disorder (GAD)
Number of subjects: 227
Study 28032323 — intervention group
Group type: COMPARATOR
Intervention: Participants without migraine
Number of subjects: 227
Study 28033414 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity Pattern A (mainly mental illness and bone impairments)
Number of subjects: 5647
Study 28033414 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity Pattern B (mainly cardiovascular and metabolic disorders)
Number of subjects: 5647
Study 28034899 — intervention group
Group type: COMPARATOR
Intervention: European Society of Cardiology pathway
Number of subjects: 1218
Study 28034899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-STEACS pathway
Number of subjects: 1218
Study 28034990 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib administered for 7 days after conventional induction with cytarabine and idarubicin
Number of subjects: 0
Study 28034990 — intervention group
Group type: COMPARATOR
Intervention: Conventional induction with cytarabine and idarubicin
Number of subjects: 0
Study 28034993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with intensive chemotherapy (daunorubicin 45 mg/m2)
Number of subjects: 0
Study 28034993 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (daunorubicin 45 mg/m2)
Number of subjects: 0
Study 28035649 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted educational intervention (modified pamphlet with skin of color section, nomenclature 'melanoma skin cancer', and image of skin self-examination)
Number of subjects: 100
Study 28035649 — intervention group
Group type: COMPARATOR
Intervention: Conventional pamphlet on the 'ABCDEs' of melanoma
Number of subjects: 100
Study 28036330 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated measurement methodology for J-Tpeakc and Tpeak-Tend intervals
Number of subjects: 0
Study 28036330 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm
Number of subjects: 0
Study 28036330 — intervention group
Group type: COMPARATOR
Intervention: Semi-automated measurements
Number of subjects: 0
Study 28038669 — intervention group
Group type: EXPERIMENTAL
Intervention: New patient experience tool (25 item scale)
Number of subjects: 0
Study 28039068 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-plus-strengthening PA intervention
Number of subjects: 400
Study 28039068 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 400
Study 28039079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide 50 mg/kg (days +3 and +4) and tacrolimus/mycophenolate mofetil (T/MMF) (day +5 forward)
Number of subjects: 35
Study 28039079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide + T/MMF combination
Number of subjects: 35
Study 28039155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus abiraterone
Number of subjects: 37
Study 28039155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus abiraterone plus prednisone (5 mg twice daily)
Number of subjects: 37
Study 28039229 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography (E/e' ratio)
Number of subjects: 74
Study 28039229 — intervention group
Group type: COMPARATOR
Intervention: Resting echocardiography (E/e' ratio)
Number of subjects: 74
Study 28039229 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B type natriuretic peptide levels
Number of subjects: 74
Study 28039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive assessment using CNAP™ technology measuring pulse pressure variation (PPV) during surgery
Number of subjects: 0
Study 28039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg-raising manoeuvre
Number of subjects: 0
Study 28039250 — intervention group
Group type: EXPERIMENTAL
Intervention: T-view scoring system
Number of subjects: 20
Study 28039250 — intervention group
Group type: EXPERIMENTAL
Intervention: L-view scoring system
Number of subjects: 20
Study 28039250 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired T and L-view scores
Number of subjects: 20
Study 28039295 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd-generation CAR-T cells (1 million CAR-T cells per kg administered intravenously)
Number of subjects: 0
Study 28039295 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd-generation CAR-T cells
Number of subjects: 0
Study 28039295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously every 6 hours) or IgG
Number of subjects: 0
Study 28039367 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-414 (0.5-3.2 mg/kg every 2 weeks by intravenous infusion) plus radiation and temozolomide
Number of subjects: 45
Study 28039616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 28039616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 28039616 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study 28039616 — intervention group
Group type: COMPARATOR
Intervention: N-Acetylcysteine
Number of subjects: 0
Study 28040280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker rhythm
Number of subjects: 300
Study 28040280 — intervention group
Group type: COMPARATOR
Intervention: IVC
Number of subjects: 300
Study 28040280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker rhythm (after propensity matching)
Number of subjects: 300
Study 28040280 — intervention group
Group type: COMPARATOR
Intervention: IVC (after propensity matching)
Number of subjects: 300
Study 28040318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 30
Study 28040992 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TWEAK levels
Number of subjects: 139
Study 28040992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo scores, MES-UC, SES-CD, CRP, fecal calprotectin
Number of subjects: 139
Study 28040992 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 139
Study 28041583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab plus miniCHOP regimen (1000 mg total dose of intravenous ofatumumab, 25 mg/m2 of cyclophosphamide, doxorubicin, vincristine, and prednisone) with pre-phase treatment (oral vincristine 1 mg total dose 1 week before cycle 1 and oral prednisone 60 mg total dose for 4 days before cycle 1)
Number of subjects: 120
Study 28041583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-phase treatment (oral vincristine and oral prednisone)
Number of subjects: 120
Study 28041583 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 120
Study 28042454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 18
Study 28043455 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-point score derived from 6 variables (birth weight, clinical syndrome or abnormal karyotype, surgeon Norwood volume or year, anatomic subtype, ascending aorta size, obstructed pulmonary venous return)
Number of subjects: 549
Study 28043455 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 549
Study 28043488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyaditum resae (NR) - daily administration of 10 doses
Number of subjects: 0
Study 28043939 — intervention group
Group type: EXPERIMENTAL
Intervention: Root tear
Number of subjects: 227
Study 28043939 — intervention group
Group type: COMPARATOR
Intervention: No root tear
Number of subjects: 227
Study 28043939 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscal morphology (other types of tears)
Number of subjects: 227
Study 28044005 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobian determinant
Number of subjects: 490
Study 28044059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment (specifics not provided)
Number of subjects: 0
Study 28044059 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated LCLs from women with PMDD
Number of subjects: 0
Study 28044059 — intervention group
Group type: COMPARATOR
Intervention: Progesterone (in controls only)
Number of subjects: 0
Study 28044059 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (in PMDD LCLs)
Number of subjects: 0
Study 28044265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg twice daily for 15 weeks
Number of subjects: 50
Study 28044265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28044265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 50
Study 28045622 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-induction (EOI) minimal residual disease (MRD) assessment
Number of subjects: 3113
Study 28045622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EOI MRD level (< 0.01%)
Number of subjects: 3113
Study 28045622 — intervention group
Group type: EXPERIMENTAL
Intervention: High MRD (≥ 5%) among patients with morphologic remission
Number of subjects: 3113
Study 28045622 — intervention group
Group type: EXPERIMENTAL
Intervention: Redefining induction failure to include morphologic induction failure and/or MRD ≥ 5%
Number of subjects: 3113
Study 28045622 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction failure (morphologic or MRD ≥ 5%)
Number of subjects: 3113
Study 28045712 — intervention group
Group type: EXPERIMENTAL
Intervention: Option B+ (lifelong antiretroviral therapy)
Number of subjects: 24
Study 28045923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in addition to chemotherapy
Number of subjects: 63
Study 28045923 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 63
Study 28045969 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light filtering spectacle lenses (BF: blue-filtering anti-reflection coating; BT: brown-tinted)
Number of subjects: 80
Study 28049004 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS)
Number of subjects: 30
Study 28049004 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Oxygen Tension (TcPO2)
Number of subjects: 30
Study 28049084 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS over the left DLPFC
Number of subjects: 22
Study 28049084 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study 28049461 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Admission (VA)
Number of subjects: 202
Study 28049461 — intervention group
Group type: COMPARATOR
Intervention: Compulsory Admission (CA)
Number of subjects: 202
Study 28049470 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for mental health care based on referral information
Number of subjects: 0
Study 28049490 — intervention group
Group type: EXPERIMENTAL
Intervention: Balixafortide (POL6326) at doses of 500-2500 µg/kg
Number of subjects: 0
Study 28049490 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 0
Study 28049639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 28049662 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction program
Number of subjects: 27
Study 28050885 — intervention group
Group type: EXPERIMENTAL
Intervention: pl-VEGF165 gene therapy (2 intramuscular injections for a total dose of 2.4 mg)
Number of subjects: 210
Study 28050885 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy without prostaglandins and prostacyclins (Control group)
Number of subjects: 210
Study 28050899 — intervention group
Group type: EXPERIMENTAL
Intervention: bioactive adrenomedullin (bio-ADM)
Number of subjects: 178
Study 28050899 — intervention group
Group type: EXPERIMENTAL
Intervention: lactate
Number of subjects: 178
Study 28051798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) monotherapy
Number of subjects: 40
Study 28052755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 24658
Study 28052755 — intervention group
Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 24658
Study 28052855 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN-004 (ribaxamase)
Number of subjects: 0
Study 28052855 — intervention group
Group type: COMPARATOR
Intervention: Control (no ribaxamase)
Number of subjects: 0
Study 28052860 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients
Number of subjects: 90
Study 28052888 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ women receiving ART
Number of subjects: 246
Study 28052888 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative women
Number of subjects: 246
Study 28052888 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 246
Study 28052888 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 246
Study 28052957 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28053173 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicator amino acid oxidation (IAAO) technique with l-[1-13C]Leucine
Number of subjects: 4
Study 28053173 — intervention group
Group type: COMPARATOR
Intervention: Current protein recommendations
Number of subjects: 4
Study 28053674 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Training (EC)
Number of subjects: 59
Study 28053674 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Training + Dietary Supplement (MCVC)
Number of subjects: 59
Study 28053674 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Stretching + Dietary Supplement (MCVC)
Number of subjects: 59
Study 28053784 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS Text Messages for Prevention of Mother-to-Child Transmission of HIV
Number of subjects: 0
Study 28053784 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study 28053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-Caloric Restriction (MCD) with approximately 100 kcal/day deficit
Number of subjects: 0
Study 28053879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 0
Study 28053879 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL12
Number of subjects: 0
Study 28053879 — intervention group
Group type: COMPARATOR
Intervention: Control (serum-free media post-wounding)
Number of subjects: 0
Study 28053986 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemical vestibular ablation with 1.0 mL of 40 mg/mL nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively
Number of subjects: 20
Study 28053986 — intervention group
Group type: COMPARATOR
Intervention: Control group with home vestibular training only, 2 months preoperatively
Number of subjects: 20
Study 28054442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloreactive NK cells from haploidentical donors
Number of subjects: 0
Study 28054442 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the alloreactive NK cell population
Number of subjects: 0
Study 28055031 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized mobile application (App)
Number of subjects: 160
Study 28055031 — intervention group
Group type: COMPARATOR
Intervention: Paper instructions (Control)
Number of subjects: 160
Study 28055031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate (SPS)
Number of subjects: 160
Study 28056030 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for 12 weeks
Number of subjects: 67
Study 28056030 — intervention group
Group type: COMPARATOR
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for 24 weeks
Number of subjects: 67
Study 28056805 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (150min/week moderate or 75min/week vigorous exercise)
Number of subjects: 109
Study 28056812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN)
Number of subjects: 24
Study 28056812 — intervention group
Group type: COMPARATOR
Intervention: Normal Weight Controls (HC)
Number of subjects: 24
Study 28056812 — intervention group
Group type: COMPARATOR
Intervention: Obesity (OB)
Number of subjects: 24
Study 28056812 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up after weight rehabilitation in AN
Number of subjects: 24
Study 28056937 — intervention group
Group type: EXPERIMENTAL
Intervention: Body morphotype and composition measured using bioelectrical impedance analysis
Number of subjects: 150
Study 28056937 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cavity on chest computed tomography
Number of subjects: 150
Study 28056937 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level <3.5 g/dL
Number of subjects: 150
Study 28057014 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-EGFR therapy
Number of subjects: 1
Study 28057014 — intervention group
Group type: EXPERIMENTAL
Intervention: CART133 treatment
Number of subjects: 1
Study 28057609 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliCare apps with coach assistance (8 weeks of coaching including an initial phone call and 2 or more texts per week)
Number of subjects: 99
Study 28057644 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cysteamine 0.55% eye drops
Number of subjects: 32
Study 28057654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia exposure (3-hour exposure simulating altitude of 4000 m.a.s.l.)
Number of subjects: 0
Study 28057654 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 0
Study 28057664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab-based treatment
Number of subjects: 1443
Study 28059466 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic weights
Number of subjects: 571
Study 28059466 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-measured weights
Number of subjects: 571
Study 28059466 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth curve modeling
Number of subjects: 571
Study 28060205 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional self-awareness treatment (8 lessons with psychoeducational information and skill-building exercises)
Number of subjects: 17
Study 28060358 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation retinal implant Alpha IMS
Number of subjects: 0
Study 28060358 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation retinal implant (under assessment in a second clinical trial)
Number of subjects: 0